Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13
Date:5/8/2009

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Santarus, Inc. (Nasdaq: SNTS) today announced that a live audio webcast and accompanying slide presentation will be provided for its analyst day and investor briefing event "Santarus: What's New?".

Details of the event are as follows:

          What:     Santarus: What's New? Analyst Day and Investor Briefing

          When:     Wednesday, May 13, 2009 at 4:15 p.m. Eastern time

          Where:    www.santarus.com (under the Investor Relations link)

AGENDA

Welcome

Martha Hough, Vice President, Finance & Investor Relations, Santarus, Inc.

Santarus - What's New?

Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

Commercial Update - ZEGERID(R)/GLUMETZA(R) and Overview of Lower GI Markets

William Denby, Senior Vice President, Commercial Operations, Santarus, Inc.

MMX(R) Technology - The Benefits of Targeted Delivery to the Colon

Dr. Luigi Moro, Chief Scientific Officer, Cosmo Pharmaceuticals

Inflammatory Bowel Disease - A New Horizon

Dr. Simon Travis, Consultant Gastroenterologist, John Radcliffe Hospital, Oxford, United Kingdom; Chairman of the Scientific Committee of the European Crohn's and Colitis Organization

Budesonide MMX(R) - Clinical Development Program in Ulcerative Colitis

Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.

Traveler's Diarrhea - #1 Health Risk for Travelers to Developing Countries

Dr. Robert Steffen, Professor Emeritus, University of Zurich Centre for Travel Medicine; Director, World Health Organization Collaborating Center for Travelers' Health

Rifamycin SV MMX(R) - Clinical Development Program in Traveler's Diarrhea

Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.

Summary/Question & Answer Session

Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

          How:       Live over the Internet -- Simply log on to the Investor
                     Relations section of the company's Web site at
                     www.santarus.com

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. The company's current commercial efforts are focused on ZEGERID(R) (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension, which are indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA(R) (metformin hydrochloride extended-release tablets), which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. Budesonide MMX is being investigated in two multi-center Phase III clinical trials for the induction of remission of mild or moderate active ulcerative colitis. Rifamycin SV MMX has been investigated in a Phase II clinical program in traveler's diarrhea. More information about Santarus is available on the company's Web site at www.santarus.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an e-mail to: webcast@multivu.com.


'/>"/>
SOURCE Santarus, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America and Merrill Lynch Health Care Conference
2. Webcast Alert: Air Methods to Announce First Quarter 2009 Financial Results
3. Webcast Alert: Release of Economic Analysis Revealing $734 Billion in Savings Produced by Using Generic Medicines in 1999 - 2008
4. Gen-Probe to Webcast Two Upcoming Investor Presentations
5. Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast
6. AMERIGROUP Corporation to Webcast Annual Meeting of Stockholders on May 7, 2009
7. Sunrise to Host Conference Call and Webcast to Discuss First-Quarter 2009 Financial Results
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
9. Thoratec Schedules First Quarter Conference Call, Webcast
10. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2009 Financial Results Conference Call
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 2017 , ... With the Grand Opening Event planned for February 3, 2017, ... teams and the general public. Built in five months by Centerpoint, the 60,000 square ... basketball or pickleball courts. The space is also suitable for indoor soccer and football ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:1/16/2017)... ... January 16, 2017 , ... In 1985, ... and high-level training standards to an international multidisciplinary group of healthcare treatment providers ... a way to further its mission at the grassroots level, iaedp launched MemberSHARE, ...
(Date:1/15/2017)... ... 2017 , ... In this role, Courtney will be responsible for developing new ... allergy friendly mark. This certification program was created by ASL and the nonprofit Asthma ... more suitable for the 60+ million people living in the U.S. with asthma and ...
(Date:1/15/2017)... ... 15, 2017 , ... San Francisco Magazine recently queried area ... for 2017. Almost 1,000 nominations were submitted and a little over 500 physicians ... announced the magazine’s January 2017 issue . , Under the category of ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... When synthetic Fentanyl arrived on the streets in 2015, dealers ... free samples, inviting would-be customers to test a newly-created batch. ... The rapidly-growing demand for the ... morphine, has racked up a staggering death toll across ... recorded fentanyl sales reveals that they have sold nearly 400 ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
(Date:1/16/2017)... January 16, 2017 ... Product Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl ... Beverages, Surface Coatings & Paints), Region - ... the market was valued at USD 4.51 ... reach USD 6.41 Billion by 2021, at ...
Breaking Medicine Technology: